NasdaqCM - Nasdaq Real Time Price USD

Tempest Therapeutics, Inc. (TPST)

8.25
+0.31
+(3.85%)
At close: June 6 at 4:00:00 PM EDT
12.25
+4.01
+(48.58%)
After hours: June 6 at 7:59:57 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for TPST

Recent News: TPST

View more
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
GlobeNewswire 3 days ago
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire 25 days ago
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire last month
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP
GlobeNewswire last month
Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value
GlobeNewswire last month
Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire 2 months ago
Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire 2 months ago
FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)
GlobeNewswire 2 months ago
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
GlobeNewswire 3 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 3 months ago
Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)
GlobeNewswire 4 months ago
View more

Related Tickers

GLYC GlycoMimetics, Inc.
0.1938
-2.42%
 
CDT Conduit Pharmaceuticals Inc.
2.6900
-0.37%
 
PHIO Phio Pharmaceuticals Corp.
2.9600
+20.33%
 
TOVX Theriva Biologics, Inc.
0.4700
-0.21%
 
SILO Silo Pharma, Inc.
0.5811
-9.20%
 
KPRX Kiora Pharmaceuticals, Inc.
3.0800
-0.32%
 
EYEN Eyenovia, Inc.
4.8800
+55.41%
 
BMEA Biomea Fusion, Inc.
2.4900
+1.63%
 
SGMT Sagimet Biosciences Inc.
5.56
+16.32%
 
SCNI Scinai Immunotherapeutics Ltd.
2.5500
-21.54%